City Therapeutics prices IPO at $18 per share, raising $200M

City Therapeutics (CTY) dosed the first participant in a Phase 1 trial for CITY-RBP4, a treatment for Stargardt disease. The study will assess safety and drug activity, with initial data expected in mid-2027. CITY-RBP4 aims to reduce RBP4 production, limiting vitamin A transport to the eye. The company has two other programs in clinical testing.

City Therapeutics dosed the first participant in its Phase 1 trial of CITY-RBP4, a treatment for Stargardt disease. The trial will assess safety and efficacy, with initial data expected in mid-2027. CITY-RBP4 aims to slow retinal damage by reducing vitamin A delivery to the eye. This is the company's second program in clinical development.

CITY THERAPEUTICS, INC. (CTY) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease CITY-RBP4 is an RNAi therapeutic candidate designed to provide potent and durable suppression of RBP4, a clinically supported target in S

Jefferies initiated City Therapeutics (NASDAQ:CTY) with a buy rating and $32 price target, citing its RNAi platform and lead programs. The stock, trading at $18.67, has declined 16.7% over six months. Jefferies highlighted potential catalysts and strong cash position. The company's IPO saw high demand, with limited share allocation due to oversubscription.

City Therapeutics (CTY) raised $230M in its Nasdaq IPO, selling 12.8M shares at $18 each, including underwriters' option. The biotech firm focuses on RNA interference therapeutics. Shares began trading on Oct. 16, 2026. Joint book-runners include Goldman Sachs, Jefferies, Stifel, and Oppenheimer.

City Therapeutics (CTY) completed its upsized IPO, raising $230M by selling 12.8M shares at $18 each. The company plans to use the proceeds to advance its RNAi programs, with future catalysts tied to clinical and regulatory milestones.